Figure 1. Troxacitabine inhibits, in a dose-and time-dependent manner, in vitro proliferation of HT-29 human colon carcinoma cells




Figure 2. Activity of troxacitabine given as a continuous infusion against the human HT-29 colon tumor xenograft

Human HT-29 colon carcinoma Infusion: 6 days

5






Figure 3. Effect of infusion time on antitumor efficacy of troxacitabine against the human HT-29 colon tumor xenograft









Figure 4. Schedule dependent activity of troxacitabine in the HT-29 human colon xenograft



į.,

5